SkyWater Technology Announces Anticipated Closing Date of Fab 25 Acquisition and Receipt of Regulatory Approvals
BLOOMINGTON, Minn. & AUSTIN, Texas--(BUSINESS WIRE)--SkyWater Technology (Nasdaq: SKYT), the trusted technology realization partner, today announced that it expects to complete its previously announced acquisition of Fab 25 on June 30, 2025. The company also confirmed that all required regulatory approvals have now been obtained.
The acquisition is expected to enhance SkyWater's capabilities in foundational semiconductor manufacturing and strengthen its strategic position within North America's semiconductor ecosystem. The closing remains subject to customary conditions. SkyWater will share further information once the transaction is completed.
About SkyWater
SkyWater (NASDAQ: SKYT) is a U.S.-based semiconductor manufacturer and a DMEA-accredited Category 1A Trusted Supplier. SkyWater's Technology as a Service model streamlines the path to production for customers with development services, high-volume production and heterogeneous integration solutions in its U.S. facilities. This pioneering model enables innovators to co-create the next wave of technology within diverse categories including mixed-signal CMOS, read-out ICs, rad-hard ICs, MEMS, superconducting ICs, photonics and advanced packaging. SkyWater serves critical domestic markets including aerospace & defense, automotive, biomedical, industrial and quantum computing. For more information, visit: www.skywatertechnology.com.
SkyWater Technology Forward-Looking Statements
This press release contains 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that are based on SkyWater's current expectations or forecasts of future events, rather than past events and outcomes, and such statements are not guarantees of future performance. Forward-looking statements are subject to risks, uncertainties and assumptions, which may cause SkyWater's actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Key factors that could cause SkyWater's actual results to be different than expected or anticipated include, but are not limited to, ability to satisfy certain conditions to the proposed Fab 25 transaction on the anticipated timeframe or at all; ability to realize the expected benefits of the proposed Fab 25 transaction; ability to promptly and effectively integrate Fab 25's operations; negative effects relating to the consummation of the proposed Fab 25 transaction on the market price of SkyWater's common stock; significant transaction costs and/or unknown or inestimable liabilities; general economic and business conditions that may affect the combined company following the consummation of the proposed Fab 25 transaction; and other factors discussed in the 'Risk Factors' section of its annual report on Form 10-K and quarterly reports on Form 10-Q, and in other documents that SkyWater files with the SEC, which are available at http://www.sec.gov. SkyWater assumes no obligation to update any forward-looking statements, which speak only as of the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Law Offices of Howard G. Smith Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) common stock between , inclusive (the 'Class Period'). Tempus investors have until August 12, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 28, 2025, Spruce Point Capital published a report alleging, among other things, that Tempus' AI capabilities were overstated, and that Company's recent financial guidance revision revealed weakness in its core operations. On this news, Tempus' stock price fell $12.67, or 19.2%, to close at $53.20 per share on May 28, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; (5) the foregoing issues revealed weakness in core operations and revenue prospects; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Tempus common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
ArrePath Announces Closing of Their Next Financing Round
PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. 'We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath,' said Kevin Krause, President and CEO. 'This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria.' Following the closing of this financing, ArrePath concluded a search for a new Chair of the Board of Directors with the appointment of Diego Miralles, M.D. Dr. Miralles comes to ArrePath with extensive experience in the biotech and pharmaceutical industry in many strategic, development and leadership roles. He was recently nominated to the Board of Directors of Contineum (NASDAQ: CTNM) and serves on the Board of Artiva (NASDAQ: ARTV). Dr. Miralles, an Infectious Diseases trained clinician and scientist, has extensive executive experience including as CEO of AZURNA Therapeutics, Inc., Laronde, Inc., and Vividion Therapeutics, Inc, and President of Adaptive Therapeutics. Previous to these roles, Dr. Miralles held various senior executive and R&D leadership positions at Johnson & Johnson. Dr. Miralles received his M.D. degree from the University of Buenos Aires, completed his residency in Internal Medicine at the Mayo Clinic and a fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University. 'We are excited to welcome Dr. Miralles to the ArrePath Board of Directors,' said Kevin Krause. 'His decades of experience as an executive and board member in both private and public companies, along with his proven experience scaling emerging biotech companies, will provide invaluable insights and experience as we approach several near-term inflection points for ArrePath. I look forward to working with him as the company evolves into the next phase of growth.' 'I am really excited to join Kevin Krause, our outstanding newly appointed CEO, and the Board at ArrePath,' said Diego Miralles. 'The company's AI discovery platform which, coupled with the team's deep experience in antimicrobial development, will enable us to bring forward superior products to address unmet needs in antimicrobials. Recent approvals in antimicrobials demonstrate the continued need for improved products, a space where ArrePath will become a leader.' About ArrePath ArrePath combines the power of human intelligence with AI/ML to address the challenge of efficient drug discovery, which is a complex optimization process paired with an unimaginable number of chemical possibilities. Our AI/ML platform couples virtual and experimental compound design and testing to create efficiency at identifying novel compounds that are both active and have the attributes required to progress. To date, we have identified antibiotic hits active against three clinically novel targets. Of these, we are progressing AP-001 to focus on the large outpatient UTI market and a hospital avoidance strategy plus the potential for step-down from hospital-based IV therapies. We also have discovered multiple novel compound families active against non-tuberculous Mycobacteria (NTM). For more information on ArrePath's innovative work and mission, please visit
Yahoo
an hour ago
- Yahoo
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
PRINCETON, N.J., June 24, 2025--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath," said Kevin Krause, President and CEO. "This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria." Following the closing of this financing, ArrePath concluded a search for a new Chair of the Board of Directors with the appointment of Diego Miralles, M.D. Dr. Miralles comes to ArrePath with extensive experience in the biotech and pharmaceutical industry in many strategic, development and leadership roles. He was recently nominated to the Board of Directors of Contineum (NASDAQ: CTNM) and serves on the Board of Artiva (NASDAQ: ARTV). Dr. Miralles, an Infectious Diseases trained clinician and scientist, has extensive executive experience including as CEO of AZURNA Therapeutics, Inc., Laronde, Inc., and Vividion Therapeutics, Inc, and President of Adaptive Therapeutics. Previous to these roles, Dr. Miralles held various senior executive and R&D leadership positions at Johnson & Johnson. Dr. Miralles received his M.D. degree from the University of Buenos Aires, completed his residency in Internal Medicine at the Mayo Clinic and a fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University. "We are excited to welcome Dr. Miralles to the ArrePath Board of Directors," said Kevin Krause. "His decades of experience as an executive and board member in both private and public companies, along with his proven experience scaling emerging biotech companies, will provide invaluable insights and experience as we approach several near-term inflection points for ArrePath. I look forward to working with him as the company evolves into the next phase of growth." "I am really excited to join Kevin Krause, our outstanding newly appointed CEO, and the Board at ArrePath," said Diego Miralles. "The company's AI discovery platform which, coupled with the team's deep experience in antimicrobial development, will enable us to bring forward superior products to address unmet needs in antimicrobials. Recent approvals in antimicrobials demonstrate the continued need for improved products, a space where ArrePath will become a leader." About ArrePath ArrePath combines the power of human intelligence with AI/ML to address the challenge of efficient drug discovery, which is a complex optimization process paired with an unimaginable number of chemical possibilities. Our AI/ML platform couples virtual and experimental compound design and testing to create efficiency at identifying novel compounds that are both active and have the attributes required to progress. To date, we have identified antibiotic hits active against three clinically novel targets. Of these, we are progressing AP-001 to focus on the large outpatient UTI market and a hospital avoidance strategy plus the potential for step-down from hospital-based IV therapies. We also have discovered multiple novel compound families active against non-tuberculous Mycobacteria (NTM). For more information on ArrePath's innovative work and mission, please visit View source version on Contacts ArrePath Reena
